COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #1
Source   Share   Tweet
See all 143 studies
Late treatment study
Xia et al., ChiCTR2000029741 (Preprint)
Efficacy of Ch loroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study
Early results from a very small trial, reported within the application for a later trial. Very minimal details are provided, but we include this as the earliest published results. For COVID-19 patients with pneumonia the viral negative conversion rate was 50% (5/10) with C Q versus 20% (3/15) with lopinavir/ritonavir.
no virological cure, ↓37.5%, p=0.17
Source   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.